Human Papillomavirus

Belinda Yen-Lieberman, Ph.D., is a professor of Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. Previously, she was the Medical Director of Clinical & Molecular Virology and Serology. Since June, 2015 she became a Consultant Staff at Dept. of Laboratory Medicine, Cleveland Clinic. Dr. Yen-Lieberman has authored more than 100 articles from numerous medical journals on wide range of topics involving viruses and other infectious diseases. These Include studies on HPV, HIV, Hepatitis B, Hepatitis C viruses and tests for Herpes Simplex 1 & 2, Respiratory viruses and Tuberculosis. Dr. Yen-Lieberman serves on the Editorial boards of J Clinical Virology, J Clinical Microbiology and J of Clinical and Vaccine Immunology. She served on the CLIA subcommittees M53-An on Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency virus Guideline and CLIA MM06-A2 on Quantitative Molecular Methods for Infectious Diseases: approved guideline. She is member of the Advisory Board on the AIDS Clinical Trial Group (ACTG) Virology Quality Assurance Program. She also served on the CDC HIV Rapid Testing Quality Assurance Workgroup and the NIAID/NIH Special Emphasis Panel Study Section.

Clinical virology including CMV, hepatitis viruses, respiratory viruses, retroviruses, serology and cellular immunology

Ted E. Schutzbank, PhD received his BA in Biology from Temple University, an MS in bacteriology from Iowa State University, and his M.Phil and PhD in Microbiology under the mentorship of Dr. Harry Ginsberg at Columbia University. Dr. Schutzbank worked as a postdoctoral fellow in Dr. Arnold J. Levine’s Lab at the State University of New York, Stony Brook. His research interests lie in the area of Molecular Diagnostics as they pertain to infectious disease testing and more recently, human genomics. He has worked extensively in the development of real-time nucleic acid amplification assays for the qualitative and quantitative detection of a wide variety of organisms, to include bacterial and viral agents of human disease. Dr. Schutzbank has extensive experience in the laboratory diagnostic aspects of HIV/AIDS and was the primary investigator on an NIH grant to implement and staff a full service pediatric HIV diagnostics laboratory while he was on the faculty of the Children’s National Medical Center in Washington DC. Dr. Schutzbank has over 30 years of experience working in hospital-based and private reference clinical laboratories, as well as in the IVD R&D arena. He has consulted for several companies, to include Qiagen Inc. and Igen Inc., as well as for the United States Air Force, and the Venezuelan Ministry of Health (pre Chavez!). Currently Dr. Schutzbank is the Technical Director of Special Testing and Microbiology at St. John’s Hospital and Medical Center in Detroit, Michigan.

Molecular Diagnostics, Infectious Diseases, Genomics, Molecular Diagnostics, Assay Development, Biotechnology, Cancer, Life sciences, Clinical Research

Joakim Dillner is professor in Infectious Disease Epidemiology and Director of the BioBanking & Molecular Resource Infrastructure of Sweden (www.bbmri.se) at Karolinska Institutet. Stockholm, Sweden. He is Head of the Cervical Cancer Prevention Center at the Karolinska Hospital Laboratory and Director of the Swedish National Cervical Screening Registry. He is also responsible for the International Human Papillomavirus (HPV) Reference Center that receives and resequences new isolates of HPV and assigns the unique type numbers for new HPV types. In 2013, he started NIASC, the Nordic Center of Excellence in eScience, that is exploiting eScience for improved cancer screening programs (www.nordicehealth.se). He received the WHO/ International Agency for Research on Cancer (IARC) Senior Visiting Scientist Award for 2011-2012. He supervises several large trials of HPV screening and registry-based follow-up studies of HPV vaccination and has experience in running international networking efforts for large-scale molecular epidemiological studies. In particular, he has led several large EU consortia on infections and cancer, notably ERICBSB (Evaluation of Risk of Infections in Cancer using Biological Specimen Banks) and VIRASKIN (Viruses and skin cancer risk) in FP5 and CCPRB (Cancer Control using Population-based Registries and Biobanks) in FP6. He is PI of Swedescreen, the first started randomised trial of HPV-screening (since 1997) and was PI of the WHO HPV LabNet Global Reference Laboratory (GRL; 2006-2011).During 2002-2007, he led the Swedish National Biobanking Program (www.biobanks.se). Joakim Dillner´s research group is specializing in high-throughput molecular epidemiological studies that utilize registries and biobanks to identify epidemiologically valid study bases with samples for molecular analyses. Key methods used include mass spectrometry, Luminex and metagenomic sequencing.

BioBanking, HPV, Epidemology, Cancer research, Vaccines, Infectious Diseases

Executive Director/ CEO of HPV Awareness/Corporation HPV Awareness December 2014 - Present (11 months) Research assistant/ Research Assistant in Canada research Chair in Health Education, 2009 - November 2014 (5 years) Coordinator of the project "Strengthening community-university partnership to offer men who have sex with men of Burkina Faso an HIV prevention program adapted culturally." - Project Coordinator "Phoenix / GPS": Identify the process adaptation of two HIV prevention programs for MSM speaking French in Quebec and English speaking MSM in Ontario - Research assistant on the project "SPOT": rapid HIV test for MSM Program Leader / Program Facilitator, Maison Plein Coeur, September 2010 - December 2012 (2 years 4 months) Moderator of the Phoenix program, which combines eroticism and risk reduction. Program for HIV-positive men who have sex relationships with other men.

HPV Awareness Corporation / Corporation HPV Awareness

OB/GYN MD, heading an international non-profit volunteer medical service and education organization: Prevention International: No Cervical Cancer (PINCC). Our mission is providing education and training in single-visit cervical cancer prevention to facilities serving women without access to care in developing countries. We provide education and training to public health medical personnel in the countries we visit, establishing self-sufficient cervical cancer prevention treatment programs.

: Gynecology; non-profits; international medical service provision

Founder of HPV Awareness Corporation/Corporation de Sensibilisation VPH, 2002 President and Spokesperson, HPV Awareness since 2006 National / International HPV Expert and Spokersperson, since 2006 International Conference speaker since 2008 for WACC (Woman Against Cervical Cancer) Conference Speaker and Sexual Health Educator with Sexpressions since 2008 Coalition Priorite Cancer au Quebec, Executive Committee, Treasurer/Tresoriere, member since 2009

HPV Awareness Corporation/Corporation de Sensibilisation VPH

A cancer patient, survivor, advocate and scientist, National and International award-winner for research, scientific writing, presentation and innovation in translational and regenerative medicine, I am an unconventional thinker, who finds solutions to complex scientific and real-life problems with precision. Invite me to give a talk or webinar on "Cancer Metabolism and the Cure for Cancer" or "Human Adult Stem Cell Technologies" for your group and let's work together.

oncology; immunology; cancer metabolism and related drugs; transcriptional control and signaling in solid tumors and lymphomas; epithelial and cancer stem cell biology; genomics; biomarkers; therapeutics; pre-clinical development; clinical research outcome evaluation; toxicology; regulation of chemicals. Diversely experienced manager of finances and logistics supporting scientific research.

My work at Indiana University School of Medicine involves patient care, teaching, and research. I am board-certified in the U.S. in internal medicine and infectious diseases. I also have a Kenyan medical license. My research interests in human papillomaviruses (HPV) began in 1985 and are currently focused on 1) the natural history of HPV infections, including early events such as virus transmission, immunologic response to infection, and duration of HPV detection, and later events such as low-level persistence, viral integration, and oncogenesis, 2) epidemiology of HPV infections and HPV-associated cancers globally, 3) continued assessment of the immunogenicity, efficacy, and safety of currently-available vaccines against HPV, and 4) development of new prophylactic and therapeutic vaccines against HPV infection and disease. I have published more than 120 articles on HPV in peer reviewed journals, and am involved in six research projects at present related to HPV and cervical cancer.

1) the natural history of HPV infections, including early events such as virus transmission, immunologic response to infection, and duration of HPV detection, and later events such as low-level persistence, viral integration, and oncogenesis, 2) epidemiology of HPV infections and HPV-associated cancers globally, 3) continued assessment of the immunogenicity, efficacy, and safety of currently-available vaccines against HPV, and 4) development of new prophylactic and therapeutic vaccines against HPV infection and disease

Chapter President, Executive Director, Author, Ms. Tonyia Renee is an Advocate, Cervical cancer and endometriosis survivor and mother. Her advocacy has led her to become the National Cervical Cancer Coalition Washington DC Chapter President where we are Initiating the Dialogue, Creating the Outlet, Providing support and Delivering the information needed to STOP the spread of the Human Papillomavirus Virus. She is the author of "HPV Happened to me", serves as the Executive Director of Question Me, a nonprofit group for teen girls focused on healthy sexual choices and mentorship and speaks on local and National platforms raising awareness for HPV and vaccines.

Chapter President, Executive Director, Author, Ms. Tonyia Renee is an Advocate, Cervical cancer and endometriosis survivor and mother. Her advocacy has led her to become the National Cervical Cancer Coalition Washington DC Chapter President where we are Initiating the Dialogue, Creating the Outlet, Providing support and Delivering the information needed to STOP the spread of the Human Papillomavirus Virus. She is the author of "HPV Happened to me", serves as the Executive Director of Question Me, a nonprofit group for teen girls focused on healthy sexual choices and mentorship and speaks on local and National platforms raising awareness for HPV and vaccines.

Shailendra Saxena is a Medical Microbiologist at Centre for Cellular and Molecular Biology (CCMB) in India. His main research interest is to elucidate the molecular mechanisms of host defense during human viral infections. He has received many awards and honors including the Fogarty International Center, NIH (USA) MERIT Award, and named as “Global Leader in Science” by The Scientist magazine (USA) and “International Opinion Leader / Expert” involved in the vaccination for JE by IPIC (UK).

Epidemiology and molecular mechanisms of host-defense during human viral infections and to develop new predictive, preventive and therapeutic strategies for them.